FMR LLC - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 154 filers reported holding ALLOGENE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 7.07 and the average weighting 0.1%.

Quarter-by-quarter ownership
FMR LLC ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$79,706,262
-35.6%
25,143,931
+0.9%
0.01%
-30.0%
Q2 2023$123,842,236
+815.0%
24,917,955
+809.5%
0.01%
+900.0%
Q1 2023$13,534,158
+38.1%
2,739,708
+75.9%
0.00%0.0%
Q4 2022$9,798,128
-26.2%
1,557,731
+26.7%
0.00%0.0%
Q3 2022$13,280,000
-11.8%
1,229,658
-6.9%
0.00%
-50.0%
Q2 2022$15,058,000
+47.1%
1,320,894
+17.6%
0.00%
+100.0%
Q1 2022$10,237,000
-63.4%
1,123,668
-40.1%
0.00%
-50.0%
Q4 2021$27,982,000
+19.7%
1,875,476
+106.3%
0.00%0.0%
Q3 2021$23,368,000
+35.0%
909,250
+37.0%
0.00%
+100.0%
Q2 2021$17,313,000
-13.3%
663,849
+17.4%
0.00%
-50.0%
Q1 2021$19,962,000
+39.9%
565,491
+0.0%
0.00%
+100.0%
Q4 2020$14,271,000
-70.8%
565,422
-56.4%
0.00%
-80.0%
Q3 2020$48,942,000
-60.8%
1,297,851
-55.4%
0.01%
-64.3%
Q2 2020$124,712,000
+79.7%
2,912,477
-18.4%
0.01%
+40.0%
Q1 2020$69,419,000
-45.0%
3,570,912
-26.5%
0.01%
-28.6%
Q4 2019$126,289,000
-16.2%
4,860,966
-12.1%
0.01%
-22.2%
Q3 2019$150,771,000
-0.3%
5,531,884
-1.8%
0.02%0.0%
Q2 2019$151,244,000
-15.2%
5,632,933
-9.2%
0.02%
-14.3%
Q1 2019$178,313,000
+36.6%
6,200,543
+26.3%
0.02%
+16.7%
Q4 2018$130,492,0004,910,9870.02%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Vida Ventures Advisors, LLC 1,798,163$16,381,0009.53%
Wildcat Capital Management, LLC 2,128,370$19,389,0004.96%
TPG GP A, LLC 18,716,306$170,506,0002.11%
Pier Capital, LLC 746,669$6,802,0000.87%
Coastal Bridge Advisors, LLC 401,929$3,662,0000.84%
HARBOR CAPITAL ADVISORS, INC. 92,755$845,0000.40%
Lombard Odier Asset Management (Switzerland) SA 501,219$4,566,0000.36%
Navalign, LLC 74,271$623,0000.26%
PDT Partners, LLC 241,592$2,201,0000.19%
GSA CAPITAL PARTNERS LLP 148,804$1,356,0000.18%
View complete list of ALLOGENE THERAPEUTICS INC shareholders